Navigation Links
Fostamatinib proven to be safe but not effective
Date:1/27/2011

In a previous study, rheumatoid arthritis (RA) patients who failed to respond to methotrexate were shown to experience positive results with fostamatinib disodium (R788), an oral spleen tyrosine kinase (Syk) inhibitor that is thought to block immune cell signaling involved with bone and cartilage destruction. In the current study, RA patients who failed to respond to biologic agents were studied. In contrast to the prior study, however, fostamatinib was not effective in this group of patients, although the drug did appear to be safe. Results of this phase II trial are published in the February issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR).

Patients with RA experience inflammation, pain and swelling of their joints that often limits daily activities and can lead to permanent disability. The National Arthritis Data Workgroup estimates that 1.3 million (0.6%) of adults in the U.S. have RA, affecting two to three times as many women as men. While many RA patients are successfully treated with disease-modifying anti-rheumatic drugs (DMARDs), those with moderate to severe RA may find that newer biologically-based therapies that inhibit cytokine activity, block T cell stimulation, or modify B cell biology slow disease progression, especially when combined with methotrexate (MTX). However, there remains a subgroup of the RA patient population who do not respond to DMARDs or current biologic therapies.

The three-month double-blind, placebo-controlled trial of R788, led by Mark Genovese, M.D., from Stanford University, enrolled 219 patients with active RA who failed to respond to one or more biologic therapies (TNF inhibitor, anakinra, abatacept, or rituximab). Patients were randomly assigned in a 2:1 ratio to receive 100 mg of R788 or placebo, respectively. Efficacy and safety were evaluated over three months. Researchers evaluated changes in the disease activity score (DAS); inflammation and joint damage were assessed by MRI.

"Our findings did not find an overall difference in efficacy between the small molecule drug, R788, and placebo," noted Dr. Genovese. "However, the drug was well tolerated and clinical benefit was found in only a subset of RA patients." Results showed that the primary outcome, the ACR 201 response, as well as the ACR 50 and 70 responses, were not significantly different between the group receiving R788 and the placebo group. However, in patients who entered the trial with an elevated C-reactive protein (CRP) level, analysis suggested a meaningful difference in the ACR 20 responses between the R788 (42%) and placebo (26%) groups. Additionally MRI results demonstrated improvement in joint inflammation in those patients with the greatest disease activity.

Researchers found that the 100mg dosage of R788 was well tolerated, with the most common adverse effects being nausea and diarrhea. "We found that 100mg of R788 was a tolerable dose for chronic administration in RA," concluded Dr. Genovese. "Phase III trials of R788 need to replicate our findings and identify subpopulations most likely to respond to this novel therapy."


'/>"/>

Contact: Dawn Peters
healthnews@wiley.com
781-388-8408
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Age 50 as mammography screening threshold proven unfounded
2. United Nations Foundation Commends G8 Leaders for Accelerating Support for Proven Interventions to Improve Women's and Children's Health
3. Little Known Proven Strategy to Increase Retirement Income by 25% or More to Be Revealed in Free Webinar Thursday, June 24
4. Use of unproven mammography tool soars with Medicare coverage
5. Dana-Farber/Provenge: Approval of prostate cancer immunotherapy-new era of cancer treatments
6. Online Body Transformation Contest Proven to be a Life Changer
7. Roll-out of proven HIV/STD risk-reduction intervention with teens by community groups successful
8. Webinar Shares Proven Social Media Approach to BtoB Lead Generation
9. Biologic Joint Reconstruction Using Stem Cells Proven Successful In Patients With Arthritis
10. The Power of James Bond Symbols Proven by Dr. Emoto
11. Certified Organic Biosecur™ Product Line Proven Effective Against Foodborne Pathogens Responsible For $152 Billion in Annual Health-Related Expenses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... , ... Donna Parker, L. Ac. reads all sorts of books on ... be very practical. She wanted to write a guide/workbook that would give readers step-by-step ... prompted her in writing “ A Clear Path to a Vibrant Life : 7 ...
(Date:4/24/2017)... ... April 24, 2017 , ... A new ... the last decade, student well-being has seriously declined. "When disenfranchised youth from the ... join the Islamic State to turn the historic multi-ethnic and multi-religious powerhouses of ...
(Date:4/24/2017)... ... ... “Reflections of God’s Work”: an enlightening collection of life lessons leading each person ... author, Jerri Broglin, a survivor of great loss who gained insight on how to ... those searching for answers, as we are finding the answers that are so deep ...
(Date:4/24/2017)... ... April 24, 2017 , ... “Learning to Use Your SPIRITUAL COMPASS To Navigate ... Use Your SPIRITUAL COMPASS To Navigate Life Issues” is the creation of published author, ... the Board of Directors for CONTACT USA, and former member of the American Association ...
(Date:4/24/2017)... ... ... “The Saint with Trin, and Omega Station”: a triple feature offering nonstop ... published author, Chris Jackson. Chris Jackson grew up in Abilene, Texas. He ... District teaching English. He is heavily involved in the youth group of his local ...
Breaking Medicine News(10 mins):
(Date:4/21/2017)... , April 21, 2017 Halo Labs ... throughput biopharmaceutical particle analysis system called the Horizon at ... May 1st. The new system analyzes sub visible particulate ... time rapid particle screening as early as candidate selection ... with leading biopharma contract research organization Elion Labs ...
(Date:4/20/2017)... -- Cogentix Medical, Inc. (NASDAQ: CGNT), a global medical ... and Gynecology markets with innovative and proprietary products, ... Company as Senior Vice President, Marketing & Business ... will report directly to Darin Hammers , ... delighted that Ash has joined the Cogentix team," ...
(Date:4/20/2017)... April 20, 2017  Vivify Health, the pioneer and ... been awarded a very significant patent for the advancement ... continual care via digital health.  This landmark patent provides ... and further secures Vivify,s position as the leader in ... was the first company to apply consumer mobile devices, ...
Breaking Medicine Technology: